JGC
INSY

J. Goldman & Co’s Insys Therapeutics, Inc. INSY Stock Holding History

J. Goldman & Co’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-28,000
Closed -$814K – 366
2015
Q1 		$814K Sell
28,000
-137,000
-83% -$3.62M 0.05% 235
2014
Q4 		$3.48M Buy
165,000
+17,000
+11% +$336K 0.41% 79
2014
Q3 		$2.87M Buy
148,000
+51,750
+54% +$813K 0.17% 150
2014
Q2 		$1.5M Buy
+96,250
New +$1.56M 0.11% 166

Other funds holding INSY

JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

J. Goldman & Co's INSY Position: Q2 2015 in Review

J. Goldman & Co sold out of Insys Therapeutics, Inc. (INSY) in Q2 2015, closing a stake of 28,000 shares — an estimated $814K sold.

J. Goldman & Co first reported a position in INSY in Q2 2014 and held it in 4 quarters. The position peaked at $3.48M in Q4 2014. 146 funds tracked by Wall St. Rank hold INSY as of Q2 2015.

  • J. Goldman & Co reported no remaining Insys Therapeutics, Inc. position as of Q2 2015 after selling out during the quarter.
  • J. Goldman & Co sold 28,000 Insys Therapeutics, Inc. shares in Q2 2015, an estimated $814K.
  • J. Goldman & Co first reported a position in Insys Therapeutics, Inc. in Q2 2014 and held it in 4 quarters.
  • J. Goldman & Co's Insys Therapeutics, Inc. position peaked at $3.48M in Q4 2014.
  • 146 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q2 2015.

Based on J. Goldman & Co's 13F filing for Q2 2015, filed 14 Aug 2015.